http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111423502-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_52fcdbfd1e64be1ce60a624089be3689 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4702 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-64 |
| filingDate | 2018-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be594a8900b9988a478a396fcfe176ad http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d88f20985af462aef356984edd6269d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3f3fc6fbe19e391cb4f12e9b880c517c |
| publicationDate | 2020-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-111423502-A |
| titleOfInvention | Polypeptide, its derivative and its application in the preparation of anti-pulmonary fibrosis medicine |
| abstract | The present invention discloses a polypeptide that specifically binds to GSK-3β or a derivative of the polypeptide. The amino acid sequence of the polypeptide is derived from the A20 sequence that binds to GSK-3β; the amino acid sequence of the polypeptide is as shown in the SEQ ID NO: ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; the derivative of the polypeptide includes a chimeric peptide formed by linking the polypeptide that specifically binds to GSK-3β and a cell-penetrating peptide. The invention also discloses a pharmaceutical composition containing the same and related applications. Utilizing the polypeptide, the derivative of the polypeptide and the pharmaceutical composition of the present invention in the treatment of pulmonary fibrosis diseases can significantly inhibit pulmonary fibrosis, significantly reduce the pulmonary weight index, and significantly reduce the number of inflammatory cells in the bronchoalveolar lavage fluid. It can significantly reduce the content of hydroxyproline and collagen in lung tissue, significantly improve lung function, and has the advantages of obvious curative effect, less toxic and side effects, and safe use. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114805569-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114409733-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114409733-B |
| priorityDate | 2018-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 241.